This attached supplementary prospectus of Queensland Bauxite Ltd. has included some updated information on the original prospectus that was lodged with the ASIC on 27 September 2018. Due to the requirement to provide further information set out in this supplementary and with the company's annual accounts being lodged in the coming days which will [...]
The Board of Queensland Bauxite Ltd. is pleased to announce that its soon to be wholly owned subsidiary, Medcan Australia, has secured a Medical Cannabis Manufacture Licence under the ODC . This licence will allow Medcan, subject to individual permit issue, the ability to manufacture its range of products, including but not limited to: - Dried [...]
Queensland Bauxite Ltd. Prospectus has been prepared for an offer of up to 170,000,000 new Shares at an issue price of $0.035 per Share to raise up to $5,950,000, with a minimum subscription of $1,995,000 together with one free attaching Option for every two Shares subscribed for and issued. This Prospectus also contains the additional offers of [...]
The Board of Queensland Bauxite Ltd. is pleased to present a set of proposed resolutions and explanatory statements, which will see the merger of Medical Cannabis Limited into the Company and the acquisition of MedCan Australia, enabling the Company to have all the licences and facilities currently needed, to progress the Cannabis business and [...]
The Board of Queensland Bauxite Ltd. is pleased to advise that it has entered into a Heads of Agreement with Sebastian and Samuel Edwards to acquire their Health Food Brands. Sebastian & Samuel Edwards are the owners and directors of Hemp Hulling Co , of which QBL's subsidiary Medical Cannabis Limited owns 55%. The business relationship between [...]
The Board of Queensland Bauxite is pleased to announce a materially positive update regarding the company's research into the use of medical cannabis in autoimmune disease treatment. On the 26th of February 2018, QBL announced a Sponsored Research Agreement between Medical Cannabis Limited 's subsidiary Medical Cannabis Research Group and Professor [...]
Queensland Bauxite provides the Company's Quarterly Report. EXECUTIVE CHAIRPERSON'S REPORT On behalf of the Directors of Queensland Bauxite, I am pleased to announce an update of our activities. Operational momentum in our subsidiary MCL continued during the quarter, with significant investment delivering targeted results. Milestones included the [...]
Further to the Transformation Announcement made on 20 June 2018, the Board of Queensland Bauxite has recognised that due to current market conditions, the intended capital raise at 8c is no longer an immediate practical option. As a result, the Board has decided to amend the raising price for the recompliance. The Board has decided that the revised [...]
Queensland Bauxite is delighted to announce that Medcan Australia , has now been issued with both an Import & Export Licence under the ODC . Highlights: - ODC Import Licence secured - ODC Export Licence secured These licences now allow Medcan, subject to individual permit issue, the ability to capitalise on the significant international and local [...]
As reported in the announcement released by Queensland Bauxite Ltd. on 13th July 2018, the Notice of Meeting for the recompliance transactions is still being drafted and is yet to be reviewed by the ASX. The following table is the timeline to which the Company is currently working towards for the completion of the transactions and the recompliance [...]
A on the ASX forum was announced, Queensland Bauxite has received many questions mainly by shareholders who were daunted by the 131 page announcement and are eager to understand further the Company's current strategy. As a result, QBL has decided to work on setting up a forum on its website to answer queries and assist shareholders to understand [...]
It is obvious by the many genuine questions and observations from shareholders to Queensland Bauxite, that although six weeks was spent both by the company and ASX to make sure that the company merger/re-compliance announcement informed shareholders to the maximum, nevertheless there are still questions arising from the lengthy announcement which [...]